Prostate cancer is the most common cancer affecting American men other than skin cancer and the second leading cause of male ...

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Discover a recent study that has identified a gene that plays a role in prostate cancer susceptibility. Learn more.

Exosomes transform prostate cancer care with early detection, tailored treatments, and real-time prognosis tracking for ...

A biobank for pediatric kidney tumors plays a key role in identifying hereditary causes of Wilms tumors. New insights gained with its help enable better risk assessment for affected families and could ...

As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding ...

“For an average risk person, which would mean not African American, and somebody that doesn’t not have a family history of ...

A team of Swedish researchers has discovered that a drug traditionally meant for type 2 diabetes shows promise in keeping prostate cancer at bay.

Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...